Dupilumab reduces systemic corticosteroid exposure in children with uncontrolled moderate-to-severe asthma regardless of prior exacerbations
Hamelmann E, Deschildre A, Ducharme FM, Sher LD, De Mir I, Xia C, Gall R, Ledanois O, Jacob-Nara JA, Sacks H, Rowe PJ, et al. (2023)
In: ERS International Congress 2023 abstracts. European Respiratory Journal, 62(Suppl. 67). Sheffield: European Respiratory Society.
Kurzbeitrag Konferenz / Poster
| Veröffentlicht | Englisch
Download
Es wurden keine Dateien hochgeladen. Nur Publikationsnachweis!
Autor*in
Hamelmann, EckardUniBi;
Deschildre, Antoine;
Ducharme, Francine M.;
Sher, Lawrence D.;
De Mir, Ines;
Xia, Changming;
Gall, Rebecca;
Ledanois, Olivier;
Jacob-Nara, Juby A.;
Sacks, Harry;
Rowe, Paul J.;
Deniz, Yamo
Alle
Alle
Abstract / Bemerkung
Background: There is a need to decrease recurrent rescue systemic corticosteroid (SCS) exposure for the treatment of exacerbations in patients with asthma, especially children. Dupilumab (DPL) is a fully human mAb that blocks the shared receptor component of IL‑4/13, key and central drivers of type 2 (T2) inflammation in multiple diseases. In VOYAGE (NCT02948959), DPL was generally well tolerated, significantly reduced severe asthma exacerbations and improved lung function, in children with uncontrolled moderate-to-severe asthma.
Objective: This post hoc analysis of VOYAGE assessed DPL efficacy in reducing the need for rescue SCS in children.
Method: Children aged 6–11 years were randomized to DPL 100/200mg or placebo (PBO), every 2 weeks for 52 weeks. The annualized number of total SCS courses (including oral, IM, IV) was analysed in subgroups of patients stratified by number of exacerbations prior to VOYAGE.
Results: Unadjusted annualized total SCS courses in T2 patients with 1, 2 and ≥3 prior exacerbations were 0.49 (PBO, n=43) vs 0.16 (DPL, n=77), 0.74 (PBO, n=31) vs 0.33 (DPL, n=69), and 1.18 (PBO, n=32) vs 0.78 (DPL, n=63), respectively (FigA). DPL treatment led to fewer exacerbations (FigB).
Conclusion: In children with uncontrolled moderate-to-severe asthma, DPL was effective in reducing SCS burden related to exacerbations, regardless of prior exacerbation history.
Erscheinungsjahr
2023
Titel des Konferenzbandes
ERS International Congress 2023 abstracts
Serien- oder Zeitschriftentitel
European Respiratory Journal
Band
62
Ausgabe
Suppl. 67
Art.-Nr.
PA2101
Konferenz
ERS International Congress 2023
Konferenzort
Milan
Konferenzdatum
2023-09-09 – 2023-09-13
ISSN
0903-1936
eISSN
1399-3003
Page URI
https://pub.uni-bielefeld.de/record/2986293
Zitieren
Hamelmann E, Deschildre A, Ducharme FM, et al. Dupilumab reduces systemic corticosteroid exposure in children with uncontrolled moderate-to-severe asthma regardless of prior exacerbations. In: ERS International Congress 2023 abstracts. European Respiratory Journal. Vol 62. Sheffield: European Respiratory Society; 2023.
Hamelmann, E., Deschildre, A., Ducharme, F. M., Sher, L. D., De Mir, I., Xia, C., Gall, R., et al. (2023). Dupilumab reduces systemic corticosteroid exposure in children with uncontrolled moderate-to-severe asthma regardless of prior exacerbations. ERS International Congress 2023 abstracts, European Respiratory Journal, 62 Sheffield: European Respiratory Society. https://doi.org/10.1183/13993003.congress-2023.PA2101
Hamelmann, Eckard, Deschildre, Antoine, Ducharme, Francine M., Sher, Lawrence D., De Mir, Ines, Xia, Changming, Gall, Rebecca, et al. 2023. “Dupilumab reduces systemic corticosteroid exposure in children with uncontrolled moderate-to-severe asthma regardless of prior exacerbations”. In ERS International Congress 2023 abstracts. Vol. 62. European Respiratory Journal. Sheffield: European Respiratory Society: PA2101.
Hamelmann, E., Deschildre, A., Ducharme, F. M., Sher, L. D., De Mir, I., Xia, C., Gall, R., Ledanois, O., Jacob-Nara, J. A., Sacks, H., et al. (2023). “Dupilumab reduces systemic corticosteroid exposure in children with uncontrolled moderate-to-severe asthma regardless of prior exacerbations” in ERS International Congress 2023 abstracts European Respiratory Journal, vol. 62, (Sheffield: European Respiratory Society).
Hamelmann, E., et al., 2023. Dupilumab reduces systemic corticosteroid exposure in children with uncontrolled moderate-to-severe asthma regardless of prior exacerbations. In ERS International Congress 2023 abstracts. European Respiratory Journal. no.62 Sheffield: European Respiratory Society.
E. Hamelmann, et al., “Dupilumab reduces systemic corticosteroid exposure in children with uncontrolled moderate-to-severe asthma regardless of prior exacerbations”, ERS International Congress 2023 abstracts, European Respiratory Journal, vol. 62, Sheffield: European Respiratory Society, 2023.
Hamelmann, E., Deschildre, A., Ducharme, F.M., Sher, L.D., De Mir, I., Xia, C., Gall, R., Ledanois, O., Jacob-Nara, J.A., Sacks, H., Rowe, P.J., Deniz, Y.: Dupilumab reduces systemic corticosteroid exposure in children with uncontrolled moderate-to-severe asthma regardless of prior exacerbations. ERS International Congress 2023 abstracts. European Respiratory Journal. 62, European Respiratory Society, Sheffield (2023).
Hamelmann, Eckard, Deschildre, Antoine, Ducharme, Francine M., Sher, Lawrence D., De Mir, Ines, Xia, Changming, Gall, Rebecca, Ledanois, Olivier, Jacob-Nara, Juby A., Sacks, Harry, Rowe, Paul J., and Deniz, Yamo. “Dupilumab reduces systemic corticosteroid exposure in children with uncontrolled moderate-to-severe asthma regardless of prior exacerbations”. ERS International Congress 2023 abstracts. Sheffield: European Respiratory Society, 2023.Vol. 62. European Respiratory Journal.
Export
Markieren/ Markierung löschen
Markierte Publikationen
Web of Science
Dieser Datensatz im Web of Science®Suchen in
Google Scholar